Compare Johnson & Johnson (JNJ) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vistra Corp — how do they compare? Johnson & Johnson trades at $260.42 (market cap $618.09B), while Vistra Corp trades at $160.66 (market cap $52.41B). The key difference: Johnson & Johnson is far larger — about 11.8× Vistra Corp's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Vistra Corp for 32 Days on average.
| JNJ | VST | |
|---|---|---|
Market Cap | $618.09B | $52.41B |
Volume | 6,050,983 | 11,278,074 |
Sector | Health | Utilities |
52-Week High | $278.43 | $210.85 |
52-Week Low | $186.00 | $134.71 |
Typical Hold Time | 129 Days | 32 Days |
Enterprise Value | $646.37B | $74.34B |
Dividend Yield | 2.09% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Vistra Corp. (VST) trades at $160.84, down 3.53% over the past day, amid mixed quarterly earnings but strong analyst support. The stock shows a bullish technical trend with support at $152 and resistance at $164, while fundamentals reflect robust profitability with an 11.55% net income margin and 75.73% ROE. Recent developments include a $4.2 billion US loan to expand nuclear power output and a 20-year power supply agreement with New Era Energy, positioning Vistra to capitalize on AI-driven electricity demand.
Outlook remains positive given Wall Street's consensus price target of $215.23, implying 34% upside, though risks include earnings volatility and high valuation multiples. Investment appeal hinges on execution of growth initiatives in nuclear and data center power markets, with institutional confidence underscored by Peter Thiel's significant stake.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
